Evaluation of safety and efficacy of Unani Add-on regimen in preventing the progression of severity of the disease in hospitalized SARS-CoV2 tested positive asymptomatic /mild to moderate symptomatic COVID-19 cases- A Randomised Controlled Clinical Trial

Authors

  • Asim Ali Khan Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Naseem Akhtar Ayurvedic and Unani Tibbiya College & Hospital (AUTCH), New Delhi
  • Naheed Parveen Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Pradeep Kumar Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Ghazala Javed Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Pawan Kumar Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Rampratap Meena Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Jamal Akhtar Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Nighat Anjum Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Usama Akram Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Nauman Saleem Ayurvedic and Unani Tibbiya College & Hospital (AUTCH), New Delhi
  • Tamanna Nazli Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Anirban Rej Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Shoeb Mumtaz Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India

DOI:

https://doi.org/10.3329/bjms.v21i4.60290

Keywords:

COVID-19; Immunity; Quality of life; Randomized Controlled Trial; WHO QoL; RT-PCR

Abstract

Objectives: The study aimed to establish the effectiveness of Unani add-on regimen by comparing theduration required for change in disease status from COVID-19 positive asymptomatic / mildto moderate symptomatic patients to asymptomatic negative.

Methods: This single-centric, randomized, twin arm, controlled, clinical trial was carried out on a totalnumber of 62 RT-PCR confirmed COVID-19 patients. The Intervention group (IG) receivedUnani Regimen (Khameera Marwareed and Unani Joshanda) in addition to the conventional management, while the Control group (CG) received only conventional management.

Results: It was observed that 16 (51.6%) patients in Intervention Group and 3 (9.4%) patients incontrol group became negative for COVID-19 at day 7 and remaining 13 out of 15 (93.5%) patients in Intervention Group and 20 out of 28 (74.1%) patients in control group becamenegative for COVID-19 at day 14 .This effect of the Unani Regimen in comparison to thecontrol group was statistically significant (p =0.003).

Conclusions: It can be concluded that the change of COVID-19 positive asymptomatic / mild to moderate symptomatic patients to RT-PCR negative was much earlier in the add-on Unani regimen group as compared to control group.

Bangladesh Journal of Medical Science Vol. 21 No. 04 October’22 Page : 901-911

Downloads

Download data is not yet available.
Abstract
53
PDF
62

Downloads

Published

2022-09-11

How to Cite

Khan, A. A. ., Akhtar, N. ., Parveen, N. ., Kumar, P. ., Javed, G. ., Kumar, P. ., … Mumtaz, S. . (2022). Evaluation of safety and efficacy of Unani Add-on regimen in preventing the progression of severity of the disease in hospitalized SARS-CoV2 tested positive asymptomatic /mild to moderate symptomatic COVID-19 cases- A Randomised Controlled Clinical Trial. Bangladesh Journal of Medical Science, 21(4), 901–911. https://doi.org/10.3329/bjms.v21i4.60290

Issue

Section

Original Articles